Agios Pharmaceuticals (AGIO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $31.32, -3.09% vs the prior close of $32.32.
- Volume 952.66K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AGIO slides 3.1% to $31.32. Closed at $31.32, -3.09% vs the prior close of $32.32. Day range $31.16–$32.35, opened at $32.35.
AGIO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AGIO slides 3.1% to $31.32
- Closed at $31.32, -3.09% vs the prior close of $32.32. Day range $31.16–$32.35, opened at $32.35.
- Volume was 952.66K shares, 0.9x its 50-day average of 1.04M.
- Price is -5.3% vs its 50-day average ($33.06) and +0.1% vs its 200-day average ($31.27).
- 52-week range $22.24–$46.00; today's close sits at 38% of that range, 31.9% below the 52-week high.
Oct 15, 2026 — AGIO jumps 4.4% to $32.32 on 2.0x normal volume
- Closed at $32.32, +4.36% vs the prior close of $30.97. Day range $31.35–$32.84, opened at $31.70.
- Volume was 2.05M shares, 2.0x its 50-day average of 1.01M — unusually heavy trading.
- Price is -2.3% vs its 50-day average ($33.07) and +3.4% vs its 200-day average ($31.25).
- 52-week range $22.24–$46.00; today's close sits at 42% of that range, 29.7% below the 52-week high.
Oct 14, 2026 — AGIO rises 2.5% to $30.97
- Closed at $30.97, +2.52% vs the prior close of $30.21. Day range $29.67–$31.11, opened at $30.07.
- Volume was 930.90K shares, 0.9x its 50-day average of 1.02M.
- Price is -6.3% vs its 50-day average ($33.06) and -0.8% vs its 200-day average ($31.23).
- 52-week range $22.24–$46.00; today's close sits at 37% of that range, 32.7% below the 52-week high.
Oct 13, 2026 — AGIO dips 2.0% to $30.21, a 1-month low, 3 down days in a row
- Closed at $30.21, -1.98% vs the prior close of $30.82. Day range $30.10–$30.99, opened at $30.60.
- Volume was 1.17M shares, 1.1x its 50-day average of 1.02M.
- Price is -8.7% vs its 50-day average ($33.08) and -3.2% vs its 200-day average ($31.21).
- 52-week range $22.24–$46.00; today's close sits at 34% of that range, 34.3% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — AGIO slides 3.1% to $30.82, a 1-month low
- Closed at $30.82, -3.11% vs the prior close of $31.81. Day range $30.69–$32.22, opened at $31.84.
- Volume was 647.80K shares, 0.6x its 50-day average of 1.05M.
- Price is -6.8% vs its 50-day average ($33.08) and -1.2% vs its 200-day average ($31.21).
- 52-week range $22.24–$46.00; today's close sits at 36% of that range, 33.0% below the 52-week high.
Oct 9, 2026 — AGIO dips 0.3% to $31.81
- Closed at $31.81, -0.34% vs the prior close of $31.92. Day range $31.52–$32.15, opened at $31.85.
- Volume was 835.70K shares, 0.8x its 50-day average of 1.09M.
- Price is -3.8% vs its 50-day average ($33.07) and +2.0% vs its 200-day average ($31.18).
- 52-week range $22.24–$46.00; today's close sits at 40% of that range, 30.8% below the 52-week high.
Oct 8, 2026 — AGIO rises 0.4% to $31.92 on 1.9x normal volume
- Closed at $31.92, +0.41% vs the prior close of $31.79. Day range $31.16–$32.32, opened at $31.46.
- Volume was 2.08M shares, 1.9x its 50-day average of 1.07M — unusually heavy trading.
- Price is -3.5% vs its 50-day average ($33.08) and +2.5% vs its 200-day average ($31.14).
- 52-week range $22.24–$46.00; today's close sits at 41% of that range, 30.6% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — AGIO ends flat (+0.2%) to $31.79
- Closed at $31.79, +0.22% vs the prior close of $31.72. Day range $31.07–$32.27, opened at $31.37.
- Volume was 1.67M shares, 1.6x its 50-day average of 1.06M.
- Price is -4.1% vs its 50-day average ($33.15) and +2.2% vs its 200-day average ($31.11).
- 52-week range $22.24–$46.00; today's close sits at 40% of that range, 30.9% below the 52-week high.
Oct 6, 2026 — AGIO rises 1.5% to $31.72
- Closed at $31.72, +1.50% vs the prior close of $31.25. Day range $30.79–$32.03, opened at $31.49.
- Volume was 1.28M shares, 1.2x its 50-day average of 1.05M.
- Price is -4.5% vs its 50-day average ($33.23) and +2.1% vs its 200-day average ($31.07).
- 52-week range $22.24–$46.00; today's close sits at 40% of that range, 31.0% below the 52-week high.
Oct 5, 2026 — AGIO dips 1.7% to $31.25, a 1-month low, 5 down days in a row
- Closed at $31.25, -1.73% vs the prior close of $31.80. Day range $30.78–$31.76, opened at $31.65.
- Volume was 808.70K shares, 0.8x its 50-day average of 1.05M.
- Price is -6.3% vs its 50-day average ($33.34) and +0.7% vs its 200-day average ($31.04).
- 52-week range $22.24–$46.00; today's close sits at 38% of that range, 32.1% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — AGIO dips 2.1% to $31.80, a 1-month low, 4 down days in a row
- Closed at $31.80, -2.09% vs the prior close of $32.48. Day range $31.65–$32.82, opened at $32.82.
- Volume was 569.90K shares, 0.5x its 50-day average of 1.06M — lighter than usual.
- Price is -4.9% vs its 50-day average ($33.44) and +2.5% vs its 200-day average ($31.01).
- 52-week range $22.24–$46.00; today's close sits at 40% of that range, 30.9% below the 52-week high.
- That makes 4 straight losses.
AGIO latest news & SEC filings
Every SEC filing by or about AGIO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gheuens Sarah sold 30,000 shares at $30.48 (≈$914.40K) on Aug 4, 2026
- Gheuens Sarah sold 30,000 shares at $30.48 (≈$914.40K) on Aug 4, 2026
- Gheuens Sarah sold 30,000 shares at $30.48 (≈$914.40K) on Aug 4, 2026
- Gheuens Sarah sold 30,000 shares at $30.48 (≈$914.40K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 3, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $44.74M (prior year $12.46M) (+259.3% vs Jun 30, 2025)
- Net income: -$100.70M (prior year -$112.02M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.69 (prior year -$1.93) (loss narrowed vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gheuens Sarah sold 4,007 shares at $37.56 (≈$150.50K) on Jul 1, 2026
- Gheuens Sarah sold 4,007 shares at $37.56 (≈$150.50K) on Jul 1, 2026
- Gheuens Sarah sold 4,007 shares at $37.56 (≈$150.50K) on Jul 1, 2026
- Gheuens Sarah sold 4,007 shares at $37.56 (≈$150.50K) on Jul 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade AGIO
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: Apr 29, 2026, Feb 12, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.97% (largest 4.4%).
- Liquidity: about 1.17M shares (≈$36.72M) trade per day on average.
- 52-week position: $31.32 vs a range of $22.24–$46.00 (38% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Sarah Gheuens sold 30,000 shares on Aug 4, 2026.
- Latest filings: 10-Q Jul 30, 2026; 8-K Jul 30, 2026; 8-K Jun 18, 2026.
- Share count: 59.70M shares outstanding (Jul 24, 2026), +2.8% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AGIO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 32.35 | 32.35 | 31.16 | 31.32 | 952.66K |
| Oct 15, 2026 | 31.70 | 32.84 | 31.35 | 32.32 | 2.05M |
| Oct 14, 2026 | 30.07 | 31.11 | 29.67 | 30.97 | 930.90K |
| Oct 13, 2026 | 30.60 | 30.99 | 30.10 | 30.21 | 1.17M |
| Oct 12, 2026 | 31.84 | 32.22 | 30.69 | 30.82 | 647.80K |
| Oct 9, 2026 | 31.85 | 32.15 | 31.52 | 31.81 | 835.70K |
| Oct 8, 2026 | 31.46 | 32.32 | 31.16 | 31.92 | 2.08M |
| Oct 7, 2026 | 31.37 | 32.27 | 31.07 | 31.79 | 1.67M |
| Oct 6, 2026 | 31.49 | 32.03 | 30.79 | 31.72 | 1.28M |
| Oct 5, 2026 | 31.65 | 31.76 | 30.78 | 31.25 | 808.70K |
| Oct 2, 2026 | 32.82 | 32.82 | 31.65 | 31.80 | 569.90K |
| Oct 1, 2026 | 33.25 | 33.73 | 32.42 | 32.48 | 1.70M |
| Sep 30, 2026 | 33.67 | 34.06 | 33.20 | 33.25 | 1.55M |
| Sep 29, 2026 | 33.21 | 33.55 | 32.70 | 33.30 | 416.40K |
| Sep 28, 2026 | 32.53 | 34.12 | 32.35 | 33.42 | 1.35M |
| Sep 25, 2026 | 32.93 | 33.33 | 32.54 | 32.58 | 996.50K |
| Sep 24, 2026 | 34.02 | 34.13 | 31.37 | 32.90 | 1.64M |
| Sep 23, 2026 | 34.85 | 35.09 | 34.09 | 34.19 | 752.50K |
| Sep 22, 2026 | 34.19 | 35.36 | 33.88 | 34.97 | 1.17M |
| Sep 21, 2026 | 33.70 | 34.14 | 33.30 | 33.95 | 884.50K |
About Agios Pharmaceuticals
Agios Pharmaceuticals (AGIO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1439222.
AGIO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jay T. Backstrom | Director | Jul 10, 2026 |
| Rahul D. Ballal | Director | Jun 23, 2026 |
| Jeffrey D Capello | Director | Jun 23, 2026 |
| Jacqualyn A Fouse | Director | Jun 23, 2026 |
| Kaye I Foster-Cheek | Director | Jun 23, 2026 |
| Brian Goff | Chief Executive Officer | Jun 23, 2026 |
| Maykin Ho | Director | Jun 23, 2026 |
| Adams Catherine Owen | Director | Jun 23, 2026 |
| David Scadden | Director | Jun 23, 2026 |
| Cynthia Smith | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| James William Burns | Chief Legal Officer | Jun 23, 2026 |
| Sarah Gheuens | Chief Medical Officer | Aug 6, 2026 |
| Brian Goff | Chief Executive Officer | Jun 23, 2026 |
| Cecilia Jones | Chief Financial Officer | Jun 23, 2026 |
| Tsveta Milanova | Chief Commercial Officer | Jun 23, 2026 |
| Krishnan Viswanadhan | Chief Strategy and Operations | Jun 23, 2026 |
| Theodore James Jr. Washburn | Principal Accounting Officer | Mar 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Sarah Gheuens | Sale | 30,000 | $30.48 |
| Aug 4, 2026 | Sarah Gheuens | Sale | 30,000 | $30.48 |
| Aug 4, 2026 | Sarah Gheuens | Sale | 30,000 | $30.48 |
| Aug 4, 2026 | Sarah Gheuens | Sale | 30,000 | $30.48 |
| Jul 1, 2026 | Sarah Gheuens | Sale | 4,007 | $37.56 |
| Jul 1, 2026 | Sarah Gheuens | Sale | 4,007 | $37.56 |
| Jul 1, 2026 | Sarah Gheuens | Sale | 4,007 | $37.56 |
| Jul 1, 2026 | Sarah Gheuens | Sale | 4,007 | $37.56 |
| Apr 2, 2026 | Sarah Gheuens | Sale | 2,940 | $34.71 |
| Apr 2, 2026 | Sarah Gheuens | Sale | 2,940 | $34.71 |
| Apr 2, 2026 | Sarah Gheuens | Sale | 2,940 | $34.71 |
| Apr 2, 2026 | Sarah Gheuens | Sale | 2,940 | $34.71 |
| Apr 2, 2026 | Brian Goff | Sale | 12,472 | $34.71 |
| Apr 2, 2026 | Brian Goff | Sale | 6,596 | $34.71 |
| Apr 2, 2026 | Brian Goff | Sale | 12,472 | $34.71 |
AGIO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $54.03M | $-412.78M | -7.12 | $-372.98M |
| Dec 31, 2024 | $36.50M | $673.73M | 11.64 | $-389.84M |
| Dec 31, 2023 | $26.82M | $-352.09M | -6.33 | $-296.06M |
| Dec 31, 2022 | $14.24M | $-231.80M | -4.23 | $-309.48M |
| Dec 31, 2021 | $0 | $1.60B | 26.55 | $-407.32M |
Latest balance sheet: total assets $1.11B, total liabilities $82.40M, cash $99.65M (as of Jun 30, 2026).
AGIO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $32.75 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $28.05 |
| Feb 12, 2026 | 8-K Item 2.02 (results) | $28.07 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $43.18 |
| Jul 31, 2025 | 8-K Item 2.02 (results) | $37.22 |
| May 1, 2025 | 8-K Item 2.02 (results) | $30.94 |
| Feb 13, 2025 | 8-K Item 2.02 (results) | $33.30 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $44.43 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AGIO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.